BioSpace News Archive

The rising adoption of pets and the increasing awareness among people regarding the animal health are projected to accelerate the growth of the market in the next few years.

Ventilation is a biological process which refers to the breathing in of oxygen and breathing out of carbon dioxide.

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately. “I am very pleased to welcome Jennifer, David, and Renée, three extremely accomplished executives with extensive biopharmaceutical backgrounds, to our board of directors,” said Khurem Farooq, Chief Executi

The global market for oncology/cancer drugs has been growing at a stellar pace on account of advancements in the domain of cancer research.

Rapid and substantialimprovement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment

Led by Rock Springs Capital with participation by funds and accounts advised by T. Rowe Price Associates, Inc., Andreessen Horowitz, and other major investors

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement to amend certain key terms of its Royalty-Backed Loan agreement (“Royalty-Backed Loan”) with HealthCare Royalty Partners (“HCR”). The key terms amended are summarized as follows:   Revised to provide for rep

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient has been dosed in the high-dose cohort of the Phase 1/2 (“Stage 1”) study for Type I (infantile) and Type II (late inf

Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Michael A. Kelly to its Board of Directors. Mr. Kelly is a proven leader with more than two decades of executive experience in the life sciences industry serving in various strategic finance and operations positions, including Chief Financial Officer and board member of multiple biotechnology companies. John F. Crowley, Chairman and Chief Executive Officer of A

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older. “With no currently approved therapies outside the United States to treat hemolytic anemia in sickle cell disease, the unmet need in this devastating di